Despite major technology-driven advances in the management of coronary artery disease, more than 450,000 people die from the condition in the United States each year. The morbidity and mortality associated with the disease continue to fuel the demand for products used to treat advanced cases that cannot be adequately managed via medical therapy. In the 21st century, percutaneous intervention is considered the coronary artery disease treatment of choice, with annual sales of percutaneous transluminal coronary angioplasty and coronary stenting products exceeding $2.4 billion.

This report from Medtech Insight includes analyses of technologies, products, current and forecast markets, competitors, and opportunities in the percutaneous transluminal coronary angioplasty and coronary stenting products market.